Sheel Biotech Ltd IPO Price Range is ₹59 - ₹63, with a minimum investment of ₹2,52,000 for 4000 shares per lot.
Subscription Rate
14.917x
as on 03 Oct 2025, 06:20PM IST
Minimum Investment
₹2,52,000
/ 4000 shares
IPO Status
Price Band
₹59 - ₹63
Bidding Dates
Sep 30, 2025 - Oct 3, 2025
Issue Size
₹34.02 Cr
Lot Size
2000 shares
Min Investment
₹2,52,000
Listing Exchange
NSE
as on 03 Oct 2025, 06:20PM IST
IPO subscribed over
🚀 14.917x
This IPO has been subscribed by 9.557x in the retail category and -40.651x in the QIB category.
Total Subscription | 14.917x |
Retail Individual Investors | 9.557x |
Qualified Institutional Buyers | -40.651x |
Non Institutional Investors | 19.44x |
Our ability to capitalize the opportunities and growth in the Tissue Culture industry.
Promotion of Tissue Culture industry by the Government of India.
Cordial relations with our clients.
We depend on government tenders for our revenue of operations. Any unavailability or any failure to securethese tenders in the future may adversely affect our business operations and financial conditions.
One of our business segment Tissue culture demands the highest level of precautions in quality, storage,and temperature management. Any negligence in these areas can significantly affect our businessoutcomes.
We use the proper techniques in the whole tissue culture process. Any Ineffective sterilization of tools andmedia can lead to contamination, which would adversely affect the entire culture.
Our business is subject to seasonal fluctuations that could result in delays or disruptions to our operationsduring the critical periods of our projects and cause severe damage to our premises and equipments.
Our Company is involved in certain legal proceedings/litigations. Any adverse decision in such proceedingsmay render us/them liable to penalties and may adversely affect our business and result of operations.
Our success depends largely upon the services of our Directors, Promoters and other Key ManagerialPersonnel and our ability to attract and retain them. Demand for Key Managerial Personnel in the industryis intense and our inability to attract and retain Key Managerial Personnel may affect the operations of ourCompany.
Any disruption, breakdown or shutdown of our research and development may have a material adverseeffect on our tissue culture segment, financial condition, results of operations and cash flows.
We have had negative cash flows in the past and may continue to have negative cash flows in the future.
Our Company does not own the premises through which we conduct our business operations.
There have been instances of delay in filing of GST and ESIC returns of the Company. We may be subjectto regulatory actions and penalties for any such delays and our business, financial condition and reputationmay be adversely affected.